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Abstrak
Latar belakang: Kegagalan pengobatan malaria pada uji klinik mungkin disebabkan oleh  Plasmodium 
falciparum yang rekrudesens/resisten terhadap obat antimalaria. Penelitian ini bertujuan untuk 
mengkonfirmasikan P. falciparum yang gagal pengobatan apakah disebabkan oleh parasit yang resisiten 
atau oleh karena adanya infeksi baru oleh  parasit dengan strain yang berbeda.
Metode: Penelitian ini adalah sebagian kegiatan uji klinik obat anti malaria ((artemisinin-naphthoquine/
AN versus dihydroartemisinin – piperaquine/DHP). Infeksi Plasmodium falciparum (mono infeksi atau 
infeksi campuran- P. falciparum & P. vivax) pada kasus yang gagal digenotipe untuk melihat variasi alel 
dengan 3 penanda molecular yaitu membandingkan sebelum (D0) dan sesudah pengobatan (DF) jika 
kekambuhan terjadi dengan   nested polymerase change reaction (PCR). 
Hasil: Tiga belas dari 19 P. falciparum  yang gagal pengobatan memperlihatkan hasil  PCR genotyping  sukses 
100% untuk MSP1 (D0 &DF), MSP2 (DF) dan  GLURP (D0) dan paling rendah (76,9%) untuk GLURP 
(DF). Apabila ketiga  gen dikombinasikan, hasil amplifikasi memperlihatkan  69,2% (9 of 13). Identifikasi 
alel  untuk setiap lokus gen memperlihatkan bahwa MSP1 hanya mempunyai 1 alel, baik D0 maupun DF. 
Sebaliknya untuk MSP2 dan GLURP ada tambahan alel pada D0 dan DF. Dengan membandingkan pola 
genotip P. falciparum  pada D0 dan DF setiap lokus gen, konfirmasi P. falciparum  yang resistant dan infeksi 
baru dapat ditentukan. Proporsi rekrudesens dan infeksi baru hampir sama  (masing-masing 54% dan 46%), 
di mana  8 di antara yang 13 tersebut berasal dari kelompok artemisinin-naphthoquine (AN).
Kesimpulan: Konfirmasi P. falciparum dengan membandingkan genotyping  D0 dan DF dapat membedakan 
parasit resisten dan yang menginfeksi baru dari kasus gagal pengobatan. Rekrudesens muncul dalam 17 hari sete-
lah pengobatan dan infeksi baru muncul setelah 28 hari pengobatan. (Health Journal of Indonesia. 2015;6:29-37)  
Kata kunci: P.falciparum, PCR, MSP1, MSP2, GLURP, alel
Abstract
Background: Treatment failure in clinical trial, may be caused by P. falciparum  resistant  to antimalarial 
drug. This study aimed to confirm the treatment failure cases of P. falciparum whcther caused by 
recrudescence / resistant or new infection of different strain parasite. 
Methods: This study was a part of the activity in antimalarial drug efficacy trials (artemisinin-naphthoquine/
AN versus dihydroartemisinin – piperaquine/DHP). P. falciparum infections on failure cases were 
genotyped for allelic variation in those 3 markers by comparing before (D0) and after treatment (DF) if 
parasites recurrent with nested polymerase change reaction (PCR).
Results: Thirteen of 19 P. falciparum failure cases showed PCR genotyping  completely successful  100% 
for MSP1 (D0 & DF), MSP2 (DF) and GLURP (D0) and the lowest (76,9% ) for GLURP (DF). When 
all 3 genes were combined, the amplification result showed 69.2%. Identification allele for each locus 
genes shown that MSP1 had just one  (D0 or  DF). Conversely, for MSP2 and GLURP, there were some 
additional alleles either at D0 and DF. By comparing the pattern of genotype (alleles)  P. falciparum  at 
D0 and DF each locus genes, the confirmation of P. falciparum resistant from new infection could be 
determined  The proportion of recrudescence and new infection  almost the same, 8 of 13 failed cases  were 
from artemisinin-naphthoquine (AN) group.
Conclusion: The confirmation of P. falciparum by comparing genotype at D0 and DF could determine parasite 
resistant and new infection from treatment failure cases. Recrudescence occurred within 17 days after treatment 
and new infection occurred >28 days after treatment. (Health Journal of Indonesia. 2015;6:29-37)  
Key words: P.falciparum, PCR, MSP1, MSP2, GLURP, allele
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Malaria parasites infect about 650 million people 
worldwide and P. falciparum alone leads to almost 
one million deaths per year making it the most 
virulent parasite causing malaria.1 The enormous 
efforts have been directed toward malaria control 
and prevention, however multiple factors including 
insecticide resistance in the anopheline vectors, and 
the emergence and rapid spread of drug-resistant 
parasite strains are major problems for the control 
and prevention of malaria.
Plasmodium falciparum resistant to antimalarial 
drugs remains a major problem for treatment of 
malaria infections in most endemic areas. In clinical 
trial study, treatment failure may cause by parasite 
resistant or new infection (reinfection). The PCR 
genotyping in malaria research has paved the way for 
major improvements in the understanding of parasite 
biology. The most commonly used markers for 
genotyping of P. falciparum are the surface antigens 
merozoite surface protein 1 (MSP1), merozoite 
surface protein 2 (MSP2) and the glutamate-rich 
protein (GLURP). 
World Health Organization has recommended them 
to be used in distingushing  P. falciparum resistant 
and new infection by polymerase change reaction 
(PCR) genotyping.2 These three genetic markers 
are unlinked, i.e. located on different chromosomes 
(9, 2 and 10 respectively), which form the basis 
for genotyping of Plasmodium falciparum and the 
distinguishing of recrudescent from novel infection 
in paired samples from the same patient. They are 
stable throughout the life cycle, they must have 
high allelic diversity and allow alleles to be easily 
distinguished. MSP1 was formerly known as 
gp195, p190. Sequence analysis of MSP1 reveals 
a polypeptide containing a series of variables, 
conserved or semi-conserved regions. Three allelic 
families (MAD 20, K1 and RO33), which differ 
in their sequence composition are known to occur. 
MSP2 is  gene consists of a central domain of variable 
repeats flanked by non-repeat variable sequences 
and by conserved N- and C- terminal domains. 
Within each of two recognized allelic families (FC27 
& 3D7), length polymorphisms due to the different 
number of repeat units.  
GLURP is highly immunogenic and is expressed in 
the hepatic, asexual and sexual stages of the parasite 
life cycle.3,4 These features make them attractive 
candidates for studies where identification and 
enumeration of genetically distinct P. falciparum 
parasite sub-populations are of interest. A major 
characteristic of human malaria parasites is their 
genetic diversity and an increasing number of 
studies have been reported on the epidemiology of 
Plasmodium falciparum, mainly focusing on the 
polymorphism of merozoite surface protein (MSP) 
1 and 2 genes.5-9 As such they have proven to be 
useful tools both in molecular epidemiology studies 
in different epidemiological settings as well as to 
distinguish treatment failures from new infections in 
anti-malarial drug trials.
Our study aimed to confirm P. falciparum by comparing 
genotype at D0 and DF could determine parasite 
resistant and new infection from treatment failure cases. 
METHODS
This study was a part of the activity in antimalarial 
drug efficacy trials of fixed single dose artemisinin-
naphthoquine in comparison with dihydroartemisinin 
– piperaquine in Jayapura and Maumere.10  
The subjects for this molecular study were parallel 
with in vivo study. They were followed for 42 days to 
evaluate the effectiveness the drug. The specimens 
were blood spot on filter paper at before (D0) and 
the day after treatment if the parasite recurrent  (DF). 
PCR-corrected were conducted to failed cases. 
Only patients were infected by P. falciparum or P. 
falciparum and P.vivax for these paired samples 
were included for this study  The  markers with 3 
locus genes (MSP1, MSP2 and GLURP) are used by 
comparing the genotipe (allele)  at DO and DF 
Time and study location 
This trial study was carried out in 2007 - 2008 
at four hospitals, three armed forces hospitals in 
Jayapura (Marthen Indeys/Army, SoedibjoSerdadi/
navy,  Bhayangkara/police hospitals ) and one public 
hospitals in Maumere (St Gabriel hospital). The 
molecular works for genotyping were conducted 
at The Center of Research and Development for 
Biomedical and Pharmaceutical Laboratory, NIHRD, 
Ministry of Health, Jakarta 
Sample collection
The specimens were  blood spots on filter paper or 
blood smears if the blood spots were not available. 
The blood spots and blood smears were  collected 
on day 0/ pretreatment (D0) and  on any other day 
whenever parasitological reassessment was required 
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or at day of failure (DF). The total volume of blood 
drawn from each subject  was 200 ul (2x100 ul) and 
spotted on  Whatmann 3MM filter paper then dried 
and kept in sealed plastic  at room temperature until 
extraction.
DNA preparation 
DNA was prepared by using Qiagen kit (QIAamp® 
DNA Mini Kit, Cat No. 51304) to get DNA by 
following the procedure in brochure included. We 
used 5 punch (diameter 5 mm) bood spot or a thick 
film (if  blood spots not avaiable) to be isolated.
Confirmation of P. falciparum  spesies by PCR
Confirmation species by PCR were conducted for 
D0 and DF for all failed cases.DNA were amplified 
by multiplex single round PCR  methode.3  PCR 
genotyping was conducted only for the samples if D0 
and DF were confirmed P. falciparum  either mono 
infection or mixed infection P. falciparum  and P.vivax. 
No further analysis  if the species at D0 and DF were 
different we called different species or if at D0 and 
DF were confirmed P.vivax either mono infection or 
mixed infection P. falciparum  and P.vivax.
Genotyping of P. falciparum by PCR
The pair blood spots or blood smears from failed cases 
were conducted  by PCR genotyping to differentiate 
recrudescence from re-infections (new infection). 
PCR genotyping  were performed by nested PCR and 
each marker (MSP1,2 and GLURP) was separated.3 
The primary primers (P) and nested (N) as following:
MSP1 (P1: 5’CAC ATG AAA GTT ATC AAG AAC 
TTG TC3’, P2: 3’GTA CGT CTA ATT CAT TTG 
CAC G5’; N1: 5’GCA GTA TTG ACA GGT TAT 
GG3’, N2: 3’GAT TGA AAG GTA TTT GAC5’); 
MSP2 (P1: 5’GAA GTT AAT TAA AAC ATT GTC3’, 
P2: 3’GAG GGA TGT TGC TGC TCC ACA G5’, 
N1: 5’CTA GAA CCA TGC ATA TGT CC3’, N2: 
3’GAG TAT AAG GAG AAG TAT G5’) and  GLURP 
(P1: 5’ACA TGC AAG TGT TGA TCC3’, P2: 3’GAT 
GGT TTG GGA GTA ACG5’, N1: 5’TGA ATT CGA 
AGA TGT TCA CAC TGA AC3’, N2: 3’TGT AGG 
TAC CAC GGG TTC TTG TGG5’). 
The MSP1 primers hybridize to regions within the 
conserved blocks 1 and 3, which flank the repeat and 
dimorphic regions. The MSP2 primers hybridize to the 
conserved blocks 1 and 4, which flank the repeat and 
dimorphic regions and the GLURP primers hybridize 
to the conserved regions flanking the R2 repeat region.3
Each reaction was done in a 50 ul final volume. For 
primary round PCR was used 5 ul  of DNA (template) 
that added to 45 ul of PCR mixture and 1 ul of primary 
product was used  for the nested PCR amplification 
that added to 49 ul of PCR mixture.  PCR mixture 
contained final concentration 2.5 M MgCl2, 200 uM 
DNTPs, 100 nM oligonucleotide primer pairs (MSP-
1, MSP-2, and GLURP P1&P2 and N1&N2)  and 
0.0125 units per ul taq polymerase (invitrogen).
Amplification were conducted by PCR Thermal 
cycler as following conditions: 
a) Primary PCR: For primary PCR MSP-1 
and MSP-2: Denaturation at 95°C for 5 min 
preceded 30 amplification cycles: denaturation 
for 30 s at 95°C, annealing for 30 s at 50°C and 
extension 1 min at 72°C. Whereas  for primary 
PCR GLURP: Denaturation at 95°C for 3 min 
preceded 30 amplification cycles: denaturation 
for 25 s at 95°C, annealing for 1 min  at 50°C 
and extension 5 min at 72°C.
b) Nested PCR.  For primary PCR MSP-1 and 
MSP-2: Denaturation at 95°C for 5 min 
preceded 30 amplification cycles: denaturation 
for 30 s at 95°C, annealing for 50 s at 50°C and 
extension 1 min at 72°C. Whereas  for primary 
PCR GLURP: Denaturation at 95°C for 3 min 
preceded 30 amplification cycles: denaturation 
for 25 s at 95°C, annealing for 1 min  at 50°C 
and extension 2 min at 72°C.
c) DNA product from amplification of MSP1, 
MSP2 and GLURP is electrophoresed through 
2% of agarose gels in TAE buffer with adding 
ethidium bomide (4 ul of 10 mg/ml of stock in 
100 ul buffer).  DNA was visualized by UV on 
geldoc 1000 imaging system.
If no result (no amplification), the assay was repeated 
and also included the template for nested PCR (the 
first PCR product) were diluted (1:2 or 1:5) and if the 
result still nothing, we assumed that gene locus was 
unidentified.  The visualization of the PCR product 
by electrophoresis was shown in Figure 1.
Definitions of ‘recrudescence’ and ‘new infection’
According to World  Health Organization4 (WHO) 
guidance: A ‘new infection’ is a subsequent occurring 
parasitemia in which all the alleles in parasites from 
the post-treatment sample are different from those 
in the admission sample (DO), for one or more loci 
tested. Whereas  a ‘recrudescence’, at least one allele 
at each locus is common to both paired samples2. 
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Data analysis 
Data were analysed  by  comparing the pattern of 
bands (allele) that shown up on D0 and  DF samples 
whether the same  or different allele/genotype.  The 
allelic size each  of MSP1, MSP2 dan GLURP loci 
were compared to the molecular size marker manually 
by using a ruler as following way: 1. Measure the 
distance DNA marker (in mm) from the well where 
the DNA marker was loaded to each known size band, 
example 100 bp, 200 bp, 300 bp, 400 bp  etc. 2). Make 
a linear equation regression between the distance DNA 
to log DNA marker   (example: Y= -0,011x +3,645). 
3). Determine the size of DNA sample (allele) by 
incorporating the distance DNA sample into that 
formula so the size alleles were known in log form. 4) 
Convert to antilog to get the real size allele for DNA 
sample. Size alleles ((allelic class) are allocated into 
“bins” of base pair (bp) size ranges of 40 base pairs for 
MSP1 and MSP2 and 60 bp size ranges for GLURP. 
RESULTS
Treatment failure cases
In this clinical trial, we found 19 pair treatment 
failure (TF) cases (pre and post treatment). All the 
Figure 1.  Visualization of DNA product frorn 3 genes 
(MSP1, MSP2 and GLURP)
Remarks:
The numbers 1–6 denote paired products from 3 patients. PCR 
products for each locus MSP1,MSP2, and GLURP-D0 and DF 
were subjected to 2.5% agarose gel electrophoresis in adjacent 
lanes and visualized by staining with ethidium bromide. Each 
product was sized against the molecular weight marker (pGEM 
DNA marker).
TF cases were from Jayapura, Papua and no cases 
in Maumere.  The PCR genotyping with 3 markers 
(MSP1, MSP2 and GLURP) were conducted only for 13 
TFs which malaria species at D0 and DF were confirmed 
by PCR as  P. falciparum either mono infection or mixed 
infection (P. falciparum  and P.vivax). Interestingly, all of 
13 subjects were man and the age range 20-29  years old 
(Table 1). Genotyping was not conducted for the others 
(6 of 19) because they were different species between 
D0 and DF (P.vivax at D0 and P. falciparum at DF) and 
no P. falciparum in one pair (P. falciparum and P.vivax at 
D0 but P.vivax only at DF (3 of 6, respectively, data not 
shown). Of the 13 cases treatment failure (26 specimens 
for D0 and DF), we found the species with mixed 
infection (P. falciparum and P.vivax) were dominant 
(57,7% or 15 of 26) in paired  samples.
    
Table 1. Data of 13 treatment failure cases
Sample 
No.
Sex Age
(year)
Treatment Day 0 
Day failure
Cofirmation 
species by 
PCR
1 M 24 AN Day  0
Day  35
Pf &Pv
Pf
2 M 21 AN Day  0
Day 33
Pf&Pv
Pf
3 M 20 AN Day 0
Day 17
Pf &Pv
Pf &Pv
4 M 23 DHP Day 0
Day 35
Pf &Pv
Pf & Pv
 5 M 21 DHP Day 0
Day 42
Pf &Pv
Pf &Pv
6 M 29 AN Day 0
Day 21
Pf &Pv
Pf
7 M 21 DHP Day 0
Day 35
Pf &Pv
Pf 
8 M 20 DHP Day 0
Day  35
Pf
Pf
9 M 22 DP Day 0
Day 28
Pf &Pv
Pf &Pv
10 M 23 AN Day 0
Day 42
Pf &Pv
Pf
11 M 22 AN Day 0
Day 42
Pf &Pv
Pf &Pv
12 M 20 AN Day 0
Day 42
Pf
Pf
13 M 21 AN Day 0
Day 35
Pf
Pf
 Note : AN= artemisinin-naphthoquine;  Pf= P.falciparum; Pv= 
P.vivax; M=male 
Performance of polymerase chain reaction genotyping
a. Identification of  MSP1, MSP2, and GLURP 
locus gene
Of the 13 genotyped DNA not all the samples could 
identify to three locus (MSP1, MSP2 dan GLURP). 
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PCR amplifications  were successful in 100% for 
MSP1 (D0 &DF), MSP2 (DF) and GLURP (D0), 
decreased to 92,3% (12 of 13)  for MSP2 (D0) and 
the lowest (76.9% or 10 of 13)) for GLURP (DF) and 
69,2% (9 0f 13) when  all 3 genes were combined. 
For MSP1 locus had just one allele either D0 or DF. 
Whereas for MSP2 and GLURP locus shown there 
were 2 alleles in some samples (Table 2). Therefore, 
there are 2 type of  infection was caused by single and 
multigenotype infection. Multigenotype infection 
(polyclonal infection) was  infections caused by 
two or more alleles each locus genes. Whereas 
monoclonal infection was caused by single alleles 
each locus genes.  Interestingly,  the 4 samples with 
no amplificatin, 75% (3 of 4) were found for  GLURP 
locus with day failure at the same day (D35). 
b. P. falciparum  allelic class diversity
Using a conservative bin size range of 40 basepairs 
for MSP1 and MSP2, and 60 basepairs for GLURP 
and then were grouped to allelic class.3  We compared 
the genotypes of malaria parasites collected pre- and 
post-treatment to investigate whether the parasite 
infections were the same or different. Identical pre- 
and post-treatment genotypes could result either from 
recrudescence or alternatively from reinfection with 
parasites bearing identical three locus genotypes. 
Length polymorphism was assessed in 13 P. 
falciparum paired isolates within the allelic class 
(allelic code) according to Brockman et.al.3,4
 The distribution of allelic class each locus  genes in 
13 P. falciparum paired isolates were shown in Table 
2. MSP1 locus  either at D0 or DF for all of subjects 
had  one allele (monoclonal infection) with size 
410-540 base pair. The allelic class were dominated 
by class 1 (D0) and class 3 (DF), 6 of 13 alleles, 
respectively. MSP2 locus at DO or DF for 3 subjects 
(respectively) had 2 alleles (polyclonal infection) by 
class 5, 4 of 15 alleles (D0), 4 of 16 alleles (DF) 
the distribution size for MSP2 in range 410-830 
base pair.   GLURP locus had more subjects  with 
polyclonal  infection ( 3 subjects at D0 and 5 subject 
at DF) by class 10, 5 of 16 alleles (D0) and 4 of 15 
alleles (DF); .the range size for GLURP locus was 
741-1055 base pair (Table 2).
Table 2. Allelic size and class of  MSP1, MSP2 and GLURP locus genes at D0 and DF
Sample 
No.
Day MSP1
size
MSP1
Allelic class 
MSP2
size
MSP2
Allelic class
GLURP
size
GLURP
Allelic class
Interpretation
1 D0
D35
410
448
1
2
448
410
2
1
863
863, 791
8
8, 7
New infection
2 D0
D33
484
484
3
3
582
582
5
5
1055
1055
11
11
Recrudescence
3 D0
D17
448
448
2
2
582
582,635
5
5,6
741, 942
757,942
6,10
6,10
Recrudescence
4 D0
D35
422
422
1
1
640,553
640
7,4
7
942
942
10
10
Recrudescence
5 D0
D42
448
489
2
3
635,410
608
6,1
6
757,1028
757,942
6,11
6,10
New infection
6 D0
D21
439
439
1
1
582
582
5
5
942
942
10
10
Recrudescence
7 D0
D35
422
422
1
1
582
582
5
5
942
Neg
10
-
Recrudescence
8 D0
D35
513
513
3
3
720
720
9
9
986
Neg
10
-
Recrudescence
9 D0
D28
513
513
1
1
640
640
7
7
832
1100
8
12
New infection
10 D0
D42
540
513
4
3
Neg
553,500
-
4,3
895
895, 830,
9
9,8
New infection
11 D0
D42
420
420
1
1
610
610
6
6
791,695
791,695
7, 5
7, 5
Recrudescence
12 D0
D42
526
500
4
3
830,789
830,789
11,10
11,10
1016
1016
11
11
New infection
13 D0
D35
540
480
4
3
676
676
7
7
832
Neg
8
-
New infection
Note:  Neg = negative, no amplification DNA by PCR after repeated 3 times by diluted the first PCR  
product;  “-“ no result because of no DNA  
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Of 13 genotyped samples, we determined the 
outcome  based on the WHO guidance. Proportion 
recrudescence and new infection outcome almost 
the same (46 % o and 54%,  respectively). Five of 
6 (83%) new infection outcomes were interpreted 
based on the occurrence different genotype (allelic 
size /class) in MSP1 (5 of 6) and in MSP2 (2 of 6) 
locus. Whereas, one left (1 of 6) occurred in GLURP 
locus.  Recrudescence occurred within 17 days after 
treatment and most reinfections (new infection) 
occurred >28 days after treatment (Table 3). 
Table 3. Artemisinin-naphthoquine vs 
dihydroartemisinin-piperaquine with day 
failure
Interpretation AN DHP Total
Recrudescence 4  
(D17=1, D21=1, 
D33=1,  D42=1 )
3
( D35=3) 
7
New Infection 4
(D35=2),
D42=2) 
2
(D28=1)
(D42=1)
6
Total 8 5 13
Note : AN = artemisinin-naphthoquine, DHP= 
dihydroartemisinin-piperaquine; Dn = day failure
DISCUSSION
The use of genotyping to distinguish recrudescent 
from new infections is recommended for all 
clinical antimalarial efficacy trials by the WHO. To 
adequately assess response to antimalarial therapy in 
clinical trials, the WHO recommends that patients 
be followed for a minimum of 28 days, as treatment 
failures may occur a number of weeks after therapy. 
Antimalarial efficacy trials usually occur in areas 
where malaria is endemic and, therefore, patients 
may be treated successfully but newly infected with 
parasites during the follow-up period. 
When subjects have recurrent parasitemia following 
therapy, it is not possible to clinically distinguish 
between a recrudescence due to drug failure and 
a new infection. Genotyping relies on the genetic 
diversity present in P. falciparum to distinguish 
whether recurrent parasitemia after therapy is due 
to recrudescence of the initial parasite strain or to 
infection with a new strain. To make this distinction, 
blood samples are collected at baseline and then 
at the time of recurrent parasitemia, and parasite 
genotypes from these two time points are compared. 
Because P. falciparum is haploid in the human host 
and genotyping markers are single-copy genes, each 
different allele detected by a genotyping marker 
represents a genetically distinct parasite strain. If 
the baseline and recurrent parasitemia samples have 
matching alleles, recurrent parasitemia is classified 
as recrudescence; if the two samples have different 
alleles, recurrent parasitemia is classified as a new 
infection.11
The using MSP1, MSP2 and GLURP as genetic 
markers due to those 3 locus genes have a high allelic 
genetic diversity in population mainly MSP2.12 MSP2 
is protein causing immune responses in humans and 
MSP1 and MSP2 are considered prime candidates 
for the development of blood stage malaria vaccine 
and are also suitable markers for the identification 
of genetically distinct P. falciparum parasite sub-
populations. The accuracy of the conclusions from 
in vivo efficacy anti-malarial drug trials depends 
on distinguishing between recrudescences and re-
infections which is accomplished by genotyping 
genes coding P. falciparum MSP1 and MSP2.13 
MSP1 and MSP2 also have been used to assess 
the multiplicity of infection (MOI) for detecting 
the number of clones per isolate. For both genetic 
makers, MOI was significantly higher in the isolates 
from the foothills/coastland areas as compared to 
those from the highland (P < 0.05). MSP2 had higher 
number of distinct allelic variants than MSP1.13 
The MOI was influenced neither by age nor by 
parasite density. Ogouye`mi-Hounto et.al7 showed 
a significant diversity of P. falciparum in southern 
Benin with an MOI unaffected by age or by parasite 
density. Another finding reported that the MOI of 
P. falciparum is low, reflected the low intensity of 
malaria transmission in Pahang, Malaysia.14 
Significant differences in the complexity and allelic 
diversity of MSP1 and MSP2 genes between areas 
probably reflect differences in the intensity of 
malaria transmission.13,15-19 A high endemic area 
is generally characterized by extensive parasite 
diversity and infected humans often carry multiple 
genotypes.  P. falciparum isolates from Mauritania 
exhibited a high degree of genetic polymorphism in 
MSP1 gene and most of the infected patients carried 
multiple clones of parasites reflecting the high level 
of malaria endemicity in study sites during malaria 
transmission season.20 Conversely, the parasite 
population in a low transmission area has a limited 
genetic diversity.6 
In this study, by using the MSP1, MSP2 and 
GLURP genetic markers, from 13 pairs treatment 
failure cases, the parasite recrudescent could be 
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distinguished from new infection almost the same cases 
(7 and 6 respectively). Although we found 7 parasite 
recrudescent (4 subjects treated with AN and 3 with 
DHP) based on the results of the core study both fixed- 
dose forms of ACT are confirmed very effective, safe 
and tolerate for treatment of any malaria in adults.10 Gosi 
et al.21 had been evaluated the parasite subpopulations 
and genetic diversity of the MSP1, MSP2 and 
GLURP genes during and following artesunate 
monotherapy treatment of P.falciparum malaria in 
Western Cambodia. In this area widespread coverage 
of the emergence of artemisinin resistance had been 
reported. The result showed that at baseline, 31% of 
infections were polyclonal for one or more genes. 
Patients with recurrent malaria were significantly 
more likely to have polyclonal infections than 
patients without recurrence. (seven of nine versus 36 
of 127; P = 0.004).
This study had a weakness due to the positive control 
for allelic family each gene not included. Congpuong 
et al9 reported that the study which was conducted in 
Thailand for 3 endemic area: Tak, Kanchanaburi and 
Ranong provinces, the distribution of allelic families 
MSP1 was significantly different among Tak, 
Kanchanaburi and Ranong but not for MSP2.  K1 
and MAD20 were the predominant allelic families 
at the MSP1 gene, whereas alleles belonging 3D7 
were more frequent at the  MSP2 gene. Similar result 
with study which performed in Pahang, Malaysia 
where RO33 and 3D7 were the most predominant 
circulating allelic families. The findings showed that 
P. falciparum has low allelic diversity with a high 
frequency of alleles.16 The GLURP gene had the least 
diverse allele. Population structure of P. falciparum 
isolates from Tak and Ranong was quite similar as 
revealed by the presence of similar proportions of 
MAD20 and K1 alleles at MSP1 loci.9
Handayani et al had been conducted genotyping 
to determine the genetic diversity for subjects of 
monitoring antimalarial drug (Dihidroartemisisnin/
DHP) in Kalimantan and Sulawesi.22 The study also 
used the same methods and markers which were 
used for PCR genotyping. We got the same result in 
detection allele for MSP1 locus namely that locus 
had just one allele (one genotype).  Conversely, for 
MSP2 locus, even though it had 2 alleles beside one 
alleles, but the frequencies higher than our result 
(67.5% or 79 / 117 compare 15.4% or 2/13) and 
lower  for GLURP locus (12.5% or 14/112 compare 
23% or 3/13).  In our study,  PCR amplifications  to 
these 3 loci were successful in 100% for MSP1 either 
D0 or DF, as well MSP2- DF, conversely for GLURP 
the successful 100 % only for D0 but it was very 
low at DF (76.9% or 10/13). When we compare this 
result (GLURP-DF) with the Kalimantan/Sulawesi 
samples, the successful to amplify the allele in this 
locus was lower (76.9% compare 80.99% or 98/121).
Brockman et al4 reported that the amplification 
was possible for all three loci with as few as three 
parasites/ml of blood (0.003 parasite/ul). This level 
of sensitivity is well within the range acceptable for 
the PCR and goes beyond the limits of microscopic 
detection. In fact, our results, not all of 3 locus genes 
identified successfully. We found 4 of 13 (31%) 
with no amplification. Interestingly, 75% (3 of 4) 
were found for  GLURP locus (no.7, 8 and 13) with 
day failure on the same day (D35). Although we 
had tried to repeat the assay with different dilution 
for the first PCR product (assumed that there was 
inhibitors in DNA suspension), the results were 
still nothing. If we considered the parasite count for 
these 3 samples,  the DNA should be enough to be 
amplified. In this study, these 3 samples had 777, 
10525 and 846 parasite/ul, respectively. It suggested, 
the result with no amplification of DNA not caused 
by less source of DNA. The possibility that parasites 
carrying a particular allelic variant might be selected 
for or against by naturally acquired immunity. The 
levels and specificity of these immune responses 
can vary among individuals.  In a number of studies, 
reported that P. falciparum populations in endemic 
areas are extremely diverse, the parasite genotypes 
were unique for each individual analyzed.14
Minor differences in length and position of PCR 
primers are known to affect the efficiency of 
amplification. Furthermore, different alleles of the 
same genetic marker are amplified with varying 
efficiency, probably because of different length 
and/or sequence composition. Therefore, the fact 
that a particular genotype pattern is not detected by 
PCR does not definitely exclude its presence in the 
sample. Confidence in determining identical parasite 
infections increases with the number of loci analyzed, 
as different parasites might be identical on one locus 
but might differ on other loci. Increasing the number 
of marker genes to be analyzed greatly enhances 
the probability of detecting genetically different P. 
falciparum infections. Now, occur another question 
“why the 3 samples with  no DNA amplifications 
occurred  only or the GLURP?” Are there by chances? 
Or are there a relationship  between  gametocyt at D0 
with GLURP locus? As mentioned the above GLURP 
is highly immunogenic and is expressed in the hepatic, 
asexual and sexual stages of the parasite life cycle.10 
Health Science Journal of IndonesiaSalwati and Tjitra36
On the other hand the other sample (no. 10, D0) 
the result also nothing. But the case was different, 
the  DNA couldn’t be amplified it might be caused 
of the concentration of DNA template was less. If 
we noticed that  sample at D0 by microscopy was 
detected P. vivax infection,  but after confirmation by 
PCR was detected mixed infection (P. falciparum and 
P. vivax, Table 1). It means, at D0 it might be, parasite 
density of P. falciparum  under microscopy level, so 
parasite s could not be read by  the microscopist. 
Of the 4 samples were not identified completely for 
the 3 locus genes, two of that samples (no.7 and 
8), the results were interpreted as recrudescence 
eventhough the GLURP at DF did not give the 
result. The reasons were firstly, MSP1 and MSP2 
were detected completely well in the same allele. 
Secondly we refer to MSP2 result based on some 
studies, MSP2 provided a more accurate measure 
of treatment outcomes recrudescence and new 
infection10 and highly discriminatory and have used 
it alone to characterize P. falciparum populations.14
The worries to misclassify as recrudescence could be 
excluded because none gametocyt occurred at DF. 
The presence of gametocytes in blood specimens 
can confound genotyping analyses.14 Outcomes can 
be misclassified as recrudescence if asexual parasites 
are cleared but gametocytes originating from the 
primary episode are detected at the time that a 
subsequent episode is diagnosed. It suggested that 
confounding as a result of gametocytemia was not a 
problem in our study. Another two samples (no. 10 
and 13), although one  loci did not amplify (MSP2, 
D0 and GLURP, DF, respectively), but at least one 
loci  (MSP1) had different alleles between D0 and 
DF, so  we interpretate them as new infection.
In this study, the days failure very variable (Table 3). 
Recrudescence occured after 17 days after treatment 
and new infection after 28 days after treatment. Day 
failures were caused artemisinin-naphthoquine   more 
variable than DHP treatment According to Snounou 
et.al14 persistence or reoccurrence of parasites up to 28 
days post-treatment is an indication of drug resistance 
of the infecting parasite. Such delayed clearance 
or reoccurrence can be caused by either an inherent 
inefficacy of the drug in vivo, or by the presence of 
parasites that are genetically resistant to the drug.
In conlusion, our results shows that the confirmation 
of P. falciparum by comparing genotype at D0 
and DF could determine parasite resistant and new 
infection from treatment failure cases.  Day failures 
were caused artemisinin-naphthoquine more variable 
than DHP treatment. Recrudescence occurred within 
17 days after treatment and new infection occurred > 
28 days after treatment.
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